NMTC
NeuroOne Medical Technologies Corporation
Set alert
0.93 USD -0.04 -4.39%
0.87 Day range 1.02
0.804 52-week range 5.89
- YTD
- -79.62%
- 1 year
- -80.48%
- Open
- 0.97
- Prev close
- 0.9698
- Mkt cap
- 8.44M
- Vol
- 33.83K
- Avg vol
- 346.82K
- EPS
- -0.99
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.87
- High
- 1.02
- Forward P/E
- -2.65
- Beta
- 0.91
- Short ratio
- 0.60
- Inst. own
- 19.43%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.81312
- 200-d avg
- 0.92463
- 1y target
- 0.00
Key statistics
- Market cap
- 22.88M
- Enterprise value
- 23.04M
- Trailing P/E
- 0.00
- Forward P/E
- -2.65
- PEG ratio
- 0.00
- Price / sales
- 5.83
- Price / book
- 6.87
- EPS (TTM)
- -0.46
- Beta
- 0.91
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 3.92M
- Revenue growth
- 31.10%
- Free cash flow
- -6.99M
- Total cash
- 1.62M
- Total debt
- 290.09K
- Return on equity
- -349.13%
- Shares outstanding
- 30.84M
- Short % of float
- 0.32%
- 50-day average
- 0.81312
- 200-day average
- 0.92463
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
NMTC Revenue — quarterly 1.97M
NMTC Net income — quarterly -2.01M
NMTC EPS — quarterly -0.23
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 17, 2024 | Sep 1, 2024 | 0.00 | -0.11 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.10 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -0.11 | — | — |
| Feb 13, 2024 | Dec 1, 2023 | 0.00 | -0.14 | — | — |
| Dec 14, 2023 | Sep 1, 2023 | 0.00 | -0.13 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -0.20 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 15, 2023 | Alliance Global Partners | main | Buy | Buy |
| Mar 28, 2022 | Craig-Hallum | down | Buy | Hold |
| Dec 3, 2021 | Alliance Global Partners | init | — | Buy |
| Nov 15, 2021 | Craig-Hallum | init | — | Buy |
About NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- n1mtc.com
News
- NeuroOne Medical Technologies Publishes Initial Clinical Results For Its OneRF Trigeminal Nerve Ablation System
- NeuroOne® Announces Peer-Reviewed Publication of Initial Clinical Experience with OneRF® Trigeminal Nerve Ablation System
- NeuroOne Featured in New York Post on OneRF® Patient's Remarkable Journey to Overcome Debilitating Facial Pain
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- NeuroOne Secures First Pharmaceutical Industry Purchase Order For StereoCED Drug Delivery Platform; No Terms Disclosed
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- NeuroOne Medical Technologies Reports Preliminary Q4 Sales ~$3.8M , Up 38.4% YoY; Sees FY26 Sales Of ~$10.5M, Up 15.6% YoY; Includes September Purchase Order Of $4.5M
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- NeuroOne Completes Three Large-Animal StereoCED Procedures, Including Combined Drug Delivery And Brain Recording; Builds Momentum Toward Planned Launch Of The StereoCED Platform For Human Investigational Clinical Studies Later This Quarter
- Maxim Group Maintains Buy on NeuroOne Medical Tech, Lowers Price Target to $5
Your note
Sign in to keep a note on NMTC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDRLE EDWARD | Director | Stock Award(Grant) | Jun 1, 2020 | 29,435 |
| BACHINSKI THOMAS | Officer | Stock Award(Grant) | Jul 19, 2017 | 215,453 |
| BUCKMAN PAUL R | Director | Stock Award(Grant) | Jun 1, 2020 | 80,495 |
| CHRISTIANSON MARK | Officer | Sale | Jun 11, 2020 | 1,089,210 |
| FREDRICKSON WADE | Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 28, 2018 | 2,613,460 |
| KALIA SURAJ CFA | Director | Stock Award(Grant) | Jun 3, 2019 | 14,006 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AWM Investment Company, Inc. | 10.03% | 1,200,000 | 890.40K | Sep 29, 2024 |
| Vanguard Group Inc | 7.69% | 919,528 | 682.29K | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 6.68% | 798,762 | 592.68K | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.37% | 283,855 | 210.62K | Sep 29, 2024 |
| Perkins Capital Management, Inc. | 1.25% | 150,000 | 111.30K | Sep 29, 2024 |
| State Street Corporation | 0.50% | 59,499 | 44.15K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 5.96% | 712,451 | 528.64K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.73% | 207,077 | 153.65K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 1.34% | 160,800 | 119.31K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.33% | 39,988 | 29.67K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.32% | 37,969 | 28.17K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.13% | 15,540 | 11.53K | Oct 30, 2024 |